# A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

> **NCT01155362** · PHASE2 · COMPLETED · sponsor: **Celularity Incorporated** · enrollment: 50 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Human Placenta-Derived Cells PDA001 Intravenous Infusion
- **DRUG:** Vehice Control

## Key facts

- **NCT ID:** NCT01155362
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-02
- **Final completion:** 2014-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155362, "A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01155362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*